SecProbe.io

CORRESP
1
filename1.htm

RELMADA THERAPEUTICS, INC.

880 Third Avenue, 12th Floor

New York, New York 10022

October 21, 2019

VIA EDGAR

Ms. Tonya K. Aldave

Securities and Exchange Commission

100 F Street, NE

Washington, DC  20549

    RE:
    Relmada Therapeutics, Inc. (the "Company")

    Registration Statement on Form S-1

    (File No. 333-233228) (the "Registration Statement")

Dear Ms. Aldave:

The Company hereby requests,
pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration
Statement, as amended, so that such Registration Statement will become effective as of 4:00 P.M., Wednesday, October 23, 2019 or
as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to
the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

In connection with the
Company’s request for acceleration of effectiveness of the above-referenced Registration Statement, the Company acknowledges
the following:

(1)           Should
the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission
from taking any action with respect to the filing;

(2)           The
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve
the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

(3)           The
Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission
or any person under the federal securities laws of the United States.

    Very truly yours,

    RELMADA THERAPEUTICS, INC.

    By:
    /s/ Sergio Traversa

    Name: Sergio Traversa

    Title: Chief Executive Officer